Gilead Sciences

Gilead Sciences is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines for life-threatening diseases. The company's primary focus areas include HIV/AIDS, liver diseases (including hepatitis B and C), inflammation, and oncology. Gilead is committed to driving innovation through bold and transformative science to develop the next generation of life-changing medicines.

100%

The overall score is a weighted number that takes into account conflict of interest, bias, deception and other practices that undermines the credibility of the source. It is calculated as:
Analysis.OverallConflictOfInterestScore * 0.3F + Analysis.OverallBiasScore * 0.3F + Analysis.DeceptivenessScore * 0.3F + Analysis.ReadabilityScore * 0.1F

A score that takes into consideration the content for flow, interruptions with ads, and overt search engine optimization techniques that makes the content hard to understand

The Daily's Verdict

This news site is known for its high journalistic standards. It strives to maintain neutrality and transparency in its reporting, and avoids conflicts of interest. It has a reputation for accuracy and rarely gets contradicted on major discrepancies in its reporting.

Bias

100%

Examples:

No current examples available.

Conflicts of Interest

100%

Examples:

No current examples available.

Contradictions

100%

Examples:

No current examples available.

Deceptions

100%

Examples:

No current examples available.

Recent Articles

  • Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

    Gilead's Lenacapavir Shows 100% Efficacy in HIV Prevention Trials: First Zero Infections

    Broke On: Thursday, 20 June 2024 Gilead's lenacapavir shows 100% efficacy and superiority in HIV prevention trials, marking the first Phase 3 study to demonstrate zero infections. The independent data monitoring committee recommended stopping the blinded phase and offering open-label lenacapavir to all participants due to its superiority over daily Truvada. This development brings Gilead closer to introducing a new form of PrEP and broadening its HIV business.